Abstracts
Skip to Late-Breaking Abstracts »
Poster Presentation Dates
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
| # | Title | Authors | Category | Keywords |
|---|---|---|---|---|
| O22 | Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma | Daniela Bota; David E. Piccioni, MD, PhD; Renato V. LaRocca, MD; Christopher M. Duma, MD; Robert D. Aiken, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD, FACP; | Clinical Trial In Progress | Clinical trial; Dendritic cell; Immune monitoring; Neoantigens; Stem cell/cancer-initiating cell; Vaccine |
| O23 | Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI) | Pavlos Msaouel, MD, PhD; Arlene Siefker-Radtke, MD; Randy F. Sweis, MD; Amir Mortazavi; Nicholas J. Vogelzang, MD; Ulka N. Vaishampayan, MD; Thomas Bradley, MD; Manojkumar Bupathi; Luke T. Nordquist, MD, FACP; David R. Shaffer; Joel Picus; Jeffrey Yorio, MD; Shifeng Mao; Gurjyot K. Doshi; Daniel L. Spitz; Sunil Gandhi; Daniel Chong; Arash Rezazadeh Kalebasty; James Christensen; Peter Olson; Demiana Faltaos, PharmD, PhD; Ronald L. Shazer; Maria Winter; Delia Alvarez; Hirak Del-Torossian; Jonathan E. Rosenberg, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| O24 | Phase II Trial of Concurrent Nivolumab and Radiation Therapy in Chemotherapy Ineligible Muscle Invasive Bladder Cancer [NUTRA trial NCT03421652] | Ulka N. Vaishampayan, MD; Saby George, MD, FACP; Lance Heilbrun; Jordan Maier, MD; Brenda Dickow; Michael Kuettel, MD; Arthur Frazier, MD; Stacey M. Suisham, RN BSN OCN CcRP; Prahlad Parajuli, PhD; Nitin Vaishampayan, MD; Ulka N. Vaishampayan, MD | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Tumor microenvironment |
| O25 | Dominant Negative PD1 Armored CART Cells Induce Remission in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients | Cheng fei Pu; Lei Xiao, PhD | Clinical Trial In Progress | B cell; CAR T cells; Checkpoint blockade; Clinical study; Clinical trial; Leukemia/Lymphoma; T cell lineages; Targeted therapy; Tumor microenvironment |
| O26 | A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis | Matthew G. Krebs, MD PhD; Paal F. Brunsvig, MD PhD; Åslaug Helland; Nuria Vinolas Segarra; Santiago Ponce Aix, MD; Enric Carcereny Costa, MD; Manuel Dómine Gomez, MD, PhD; Jose Manuel Trigo Perez; Edurne Arriola; Rosario Garcia Campelo; James Spicer, MD, PhD; Jonathan Thompson, MD MS; Ana Laura Ortega Granados; Robert Holt, PhD; James Lorens, PhD; Muhammad Shoaib, MD; Abdul Siddiqui; Emmett Schmidt, MD PhD; Michael J. Chisamore, PhD; Enriqueta Felip, MD PhD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| O27 | Clinical Response to Tumor Infiltrating Lymphocytes (TIL) in Stage 4 Non-small Cell Lung Cancer (NSCLC) Correlates with Neoantigen-Specificity: a Phase I Trial | Chao Wang, PhD; Jamie Teer; Jiqiang Yao, PhD; Anadon Galindo Carmen M; David Noyes; Eric Toloza; John E. Mullinax, MD; Ana Landin; Jhanelle Gray; Tawee Tanvetyanon; Andreas Saltos; Linda L. Kelley, PhD; Bin Fang, PhD; John Koomen, PhD; Amod A. Sarnaik, MD; Sungjune Kim, MD PhD; Shari A. Pilon-Thomas, PhD; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD. PhD; Eric Haura, MD; Ben C. Creelan, MD, MS; | Clinical Trial In Progress | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| O28 | First-in-Class Small Molecule CA-170 Targeting VISTA: A Report on Efficacy Outcomes from a Cohort of 12 Malignant Pleural Mesothelioma (MPM) Patients in Study CA-170-101 | Marjorie G. Zauderer, MD, MS, FACP; Joshua Brody, MD; Thomas U. Marron, MD PhD; Simon Pacey; Robert Martell; Hongwei Wang; James Spicer, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy |
| O29 | Phase I study of multisite stereotactic body radiotherapy plus nivolumab and urelumab or nivolumab and cabiralizumab in patients with advanced solid tumors | Corey C. Foster, MD, MS; Jason J. Luke, MD, FACP; Robyn Hseu, CCRP, MLIS; Linda Janisch; Gini Fleming, MD; Steven J. Chmura, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors |
| O30 | A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors | Ben Markman, MBBS FRACP; Ben Tran; Hui Gan, MBBS PhD; Amy Prawira, MD; Jermaine Coward; Xiaoping Jin; Baiyong Li; Max Wang; Yu Xia; Jayesh Desai, MBBS FRACP; Jayesh Desai, MBBS FRACP; Michael Millward; | Clinical Trial In Progress | Antibody; Biomarkers; Clinical trial; Solid tumors |
| O31 | Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types | Jacob Thomas, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, M.S., M.A, M.B.A.; Ian B. Walters, MD; Giles F. Whalen, MD; Diana Hanna, MD; Vinay Duddalwar, MD; Phillip Cheng, MD; Kevin King, MD; Lilian L. Siu, MD; Anthony El-Khoueiry, MD; | Clinical Trial In Progress | Chemotherapy; Clinical trial; Dendritic cell; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| O32 | Single agent anti-tumor activity in PD-1 refractory NSCLC: phase 1 data from the first-in-human trial of NC318, a Siglec-15-targeted antibody | Anthony Tolcher, MD; Omid Hamid, MD; Jeffrey S. Weber, MD, PhD; Patricia LoRusso, DO; Kathryn Shantz; Kevin N. Heller, MD; Kevin Heller, MD; Martin Gutierrez, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors; T cell; Tumor antigens; Tumor evasion; Tumor microenvironment |
| O33 | Immune enrichment and functional T-cell receptor (TCR) frequencies predict response to immune checkpoint blockade (ICB) in selected fusion-associated sarcomas | Akash Mitra, BS; Neeta Somaiah, MD, MBBS; Anthony P. Conley, MD; Behrang Amini; Heather Lin; Beatriz Sanchez Espiridion; Celia Garcia-Prieto; Grace Mathew; Latasha Little, BS; Xingshi Song; Curtis Gumbs, BS; Cara Haymaker, PhD; Jianhua Zhang; Zachary A. Cooper, PhD; Michael D. Oberst, PhD; Chantale Bernatchez; Vinod Ravi; Dejka Araujo, MD; Maria Zarzour; John Livingston; Christina Roland, MD, MS, FACS; Najat Daw, MD; Jaime Rodriguez-Canales, MD; Alexander J. Lazar, MD, PhD; Wei-Lien Wang; Ignacio Wistuba, MD; Jean-Charles Soria, MD, PhD; Robert Benjamin; Shreyaskumar Patel; Patrick Hwu, MD; Phillip Andrew Futreal, PhD; | Clinical Trial In Progress | Bioinformatics; Checkpoint blockade; Clinical trial; Gene expression; Immune monitoring; Immunoscore; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O34 | Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High Risk Resectable Melanoma (MEL): Preliminary Results. | Diwakar Davar, MD; Arivarasan Karunamurthy; Douglas Hartman; Mignane Ka; Carmine Menna; Julie Burkette; Joe-Marc JM. Chauvin, PhD; Lucas Rubuffet; Shuowen Zhang; Quanquan Ding; Amy Rose; Kellie Sellitto; Yana G. Najjar, MD; Matthew Holtzman; James Pingpank; Shaum Sridharan; Umamaheshwar Duvvuri; Hagop Youssoufian; Barry Labinger; Arthur Krieg; John M. Kirkwood, MD; Hassane M. Zarour, MD; | Clinical Trial In Progress | Clinical trial; T cell; TLR |
| O35 | Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study | Adi Diab, MD; Igor Puzanov, MD, MSCI, FACP; Michele Maio, MD, PhD; Brendan D. Curti, MD; Mehmet A. Bilen; Karl D. Lewis, MD; Scott S. Tykodi, MD, PhD; Gregory A. Daniels, MD, PhD; Alexander I. Spira, MD, PhD, FACP; Chantale Bernatchez; Salah Eddine Bentebibel; Michael K. Wong, MD PhD FRCPC; James Larkin, MD; Ewa Kalinka, PhD, MD; Sunny Xie; Sue Currie; Ute Hoch, PhD; Wei Lin; Mary A. Tagliaferri, MD; Stina Singel; Michael E. Hurwitz, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Cytokine; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O36 | A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors | Thomas Eigentler, Dr.; Juergen Krauss; Jutta Schreiber, Dr; Carsten Weishaupt; Patrick Terheyden; Lucie Heinzerling; Peter Mohr; Benjamin Weide, MD; Sebastian Ochsenreither; Juergen C. Becker, MD, PhD; Franz-Georg Bauernfeind, Dr; Peter Brossart; Fatma Funkner; Regina Heidenreich; Sarah-Katharina Kays; Anke Muth; Tobias Seibel, II; Birgit Scheel; Oliver Schoenborn-Kellenberger; Claudia Stosnach; Angelika Daehling; Tanja Strack; Roman P. Korolkiewicz; Ulrike Gnad-Vogt, MD | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Inflammation; TLR; Tumor microenvironment; Vaccine |
| O82 | A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies | Sarina Piha-Paul, MD, Johanna Bendell, MD, Anthony Tolcher, Sara Hurvitz, MD, Amita Patnaik, MD FRCP(C), Rachna Shroff, Paula Pohlmann, Markus Zettl, Noah Hahn, MD, Anuradha Krishnamurthy, MD0, Manuela Duerr, Jian Mei, Kayti Aviano, Rushdia Yusuf, MD, MPH, Louis Matis, MD, Shane Olwill, PhD, Ingmar Bruns* , Geoffrey Ku | Clinical Trial In Progress | Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O83 | Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | Ronnie Shapira-Frommer, Marloes G. J. van Dongen, Konstantin Dobrenkov, Elliot Chartash, Fang Liu, PhD, Claire Li, Richard Wnek, Manish Patel, MD | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy |
| O85 | Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a Toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab | Mohammed Milhem, MBBS, Yousef Zakharia, MD, Diwakar Davar, MD, Elizabeth Buchbinder, MD, Theresa Medina, MD, Adil Daud, MD, Antoni Ribas, MD, PhD, Jiaxin Niu, Geoffrey Gibney, MD, Kim Margolin, MD, Anthony Olszanski, MD, RPh0, Interjit Mehmi, Takami Sato, MD, Montaser Shaheen, Aaron Morris, David Mauro, Katie Campbell, Riyue Bao, George Weiner, MD, Jason Luke, MD, FACP, Arthur Krieg, John Kirkwood, MD | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical trial; Cytokine; Dendritic cell; Inflammation; Regulatory T cell (Treg cell); Solid tumors; TLR; Tumor microenvironment |
| P368 | ZI-H04 - A novel MHC class II restricted TCR based cellular therapy targeting hTERT to treat solid tumours | Jens-Peter Marschner, MD; Mona Welschof, PhD; Miguel Forte; Eva Kristine Klemsdal; Sylvie Pollmann; Namir Hassan; Inês Cardoso, PhD | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P369 | Feasibility of a phase I personalized adoptive T-cell therapy in patients with relapsed/refractory solid tumors | Apostolia M. Tsimberidou, MD, PhD; Ali Mohamed; Stephen L. Eck, MD, PhD; Harpreet Singh; Patrick Hwu, MD; Cassian Yee, MD; Borje Andersson, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Biomarkers; Clinical trial; Solid tumors; T cell |
| P370 | The positive correlation between baseline absolute eosinophil count (AEC) in blood and clinical benefit to PD-(L)1 inhibition monotherapy | Danni Yu, PhD; Anna M. Szpurka, PhD; Michelle Carlsen; Danni Yu, PhD; Antoine Hollebecque, MD; Hyun Cheol Chung, MD, PhD; Amita Patnaik; Johanna Bendell, MD; Antoine Italiano, MD; Yung-Jue Bang, MD PhD; Chia-Chi Lin, MD, PhD; Marcus O. Butler, MD; Timothy A. Yap, MD PhD; María José de Miguel, MD; María José de Miguel, MD; Jean-Pascal Machiels, MD, PhD; Marc Peeters, MD, PhD; Wu-Chou Su, MD; Victor Moreno, MD; Yumin Zhao, PhD; Erik Rasmussen, PhD; Xiaojian Xu, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors |
| P371 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | John Lynes, MD; Victoria Sanchez; Anthony Nwankwo; Gifty A. Dominah; Xiang Wang, MS; Isac Kunnath; Samantha Dill; Gretchen K. Scott; Christi Hayes; Tianxia Wu; Marta Penas-Prado; Jing Wu; Eric Burton; John Heiss; Christopher S. Hourigan, MD, PhD; Mark R. Gilbert; Edjah K. Nduom, MD; John Lynes, MD; Edjah K. Nduom, MD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Immune monitoring; Immune suppression; Proteomics; Surgery; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P372 | Circulating Immune Cell Biomarkers Predict Response to Immune Checkpoint Inhibitor Therapy in Metastatic Breast Cancer | Jin Sun L. Bitar, MD; Colt Egelston, PhD; Susan Yost; Wanqiu Hou; Padam Simran; Paul Frankel, PhD; Mina Sedrak; Jana Portnow, MD; Joanne Mortimer, MD; Christina Yeon, MD; Arti Hurria, MD; Aileen Tang; Norma Martinez; Peter P. Lee, MD; Yuan Yuan; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; T cell; Tumor microenvironment |
| P373 | A window-of-opportunity Study of pelareorep in Early Breast Cancer (AWARE-1) | Luis Manso; Patricia Villagrasa; Nuria Chic; Juan M. Cejalvo; Yann Izarzugaza; Blanca Cantos; Salvador Blanch; Manel Juan; Blanca Gonzalez; Rita Laeufle; Gerard Nuovo; Grey A. Wilkinson, PhD; Matt Coffey; Azucena Gonzalez; Patricia Galvan; Laia Paré; Jordi Canes; Xavier Gonzalez; Aleix Prat, MD PhD; Aleix Prat, MD PhD; Joaquín Gavilá; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P374 | TCR repertoires from peripheral blood correlate with prognostic response in TNBC cancer vaccine immunotherapy | Sadanand Vodala, PhD; Andrew Nguyen, PhD; Noe Rodriguez; Peter Sieling; Charles J. Vaske; Jon Van Lew; kayvan Niazi; John H. Lee, MD; Patrick Soon-Shiong, MD, FRCS, FACS; Shahrooz Rabizadeh; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Immune suppression; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P375 | Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC) | Daniel V. Catenacci, MD; Minori Rosales; Jon M. Wigginton, MD; Hyun Cheol Chung, MD, PhD; Harry Yoon; Lin Shen; Yoon-Koo Kang; Markus Moehler; | Clinical Trial In Progress | Adoptive immunotherapy; Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Tumor antigens |
| P376 | NOUS-209: A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Anna Gorrasi, PhD; Elisa Scarselli; Maria Teresa Catanese; Cinzia Traboni; Paola Antonini; Denis Brkic; | Clinical Trial In Progress | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P377 | Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with pembrolizumab in patients with metastatic colorectal or gastric cancer. | Keun-Wook Lee, MD; Young Suk Park, MD, PhD; Joong Bae Ahn; Sun Young Rha; Hark Kyun Kim; Park Young Lee; Min-Hee Ryu; Jeeyun Lee, MD, PhD; Jin Kyung Lee; Sunjin Hwang; Seong-Jin Kiim; Tae Won Kim, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Tumor microenvironment; Tumor stroma |
| P378 | Phase II Study of Combination Ipilimumab, Nivolumab, and Panitumumab in Patients with KRAS, NRAS, and BRAF Wild-Type (WT) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) | Michael S. Lee, MD; Patrick J. Loehrer, MD; Iman Imanirad, MD; Stacey Cohen, MD; Kristen Ciombor, MD; Cheryl A. Carlson, MD/PhD; Hanna K. Sanoff, MD; Autumn J. McRee, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P379 | Title: Phase 1 Safety Study in Healthy Volunteers of AB680, a Small-Molecule Inhibitor of CD73 and Rationale for Combination Therapy in Patients with Gastrointestinal Malignancies | Devika Ashok, PhD; Irene Luu; Akshata Udyavar, Ph.D; Lixia Jin; Lijuan Fu; Elaine Ginn; Ken Lawson; Jenna Jeffrey, PhD; Manmohan R. Leleti, PhD; Jay P. Powers, PhD; Eric Connor; Andy Pennell; Daniel DiRenzo, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Amanda Garofalo; Wade Berry, BA; Matthew J. Walters, PhD; Steve W. Young, PhD; Fangfang Yin, PhD; Dominic Lai; Lisa Seitz, MA; | Clinical Trial In Progress | Bioinformatics; Biomarkers; Clinical study; Clinical trial; Immune suppression; Tumor microenvironment |
| P380 | Phase 1b/2 study of BXCL701, a small molecule inhibitor of dipeptidyl peptidases, with bempegaldesleukin (bempeg, NKTR-214) and avelumab (anti-PD-L1) in unresectable or metastatic pancreatic cancer | Louis M. Weiner, MD; Benjamin A. Weinberg, MD; Stina Singel; Cedric Burg; Diane Healey; Jonathan Zalevsky, PhD; Chetan Lathia; Willem W. Overwijk, PhD; Cristian Massacesi; Joyce Acbay; John MacDougall, PhD; Vincent O'Neill; | Clinical Trial In Progress | Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Cytokine; Monocyte/Macrophage; Solid tumors; Tumor microenvironment; Tumor stroma |
| P381 | Phase 1b/2 study of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (anti-PD-1) monoclonal antibody, in small cell neuroendocrine prostate cancer (SCNC, NEPC) | Diane Healey; Rahul Aggarwal, MD; Vincent O'Neill; Cedric Burg; Jiaoti Huang; Johann S. De Bono, MD; Eric J. Small; | Clinical Trial In Progress | Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Cytokine; Monocyte/Macrophage; Solid tumors; Tumor microenvironment; Tumor stroma |
| P382 | KEYNOTE-365 cohort D: phase 1b/2 study of pembrolizumab plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer | Leonard J. Appleman, MD, PhD; Josep Piulats; Nataliya Mar; José A. Arranz; Anthony Joshua, MD; Tina M. Mayer; Neal Shore, MD; Haiyan Wu, PhD; Charles Schloss; Evan Y. Yu; | Clinical Trial In Progress | Clinical trial |
| P384 | A phase I dose escalation and expansion study of HPN424, a PSMA-targeting T cell engager, in patients with advanced prostate cancer refractory to androgen therapy | Johanna Bendell, MD; Mark Stein, MD; Johann de Bono, MD; Richard Austin, PhD; Sue Hirabayashi; Che-Leung Law, PhD; Bryan Lemon, PhD; Holger Wesche, PhD; Aaron Weitzman, MD FACP; Lawrence Fong, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P385 | Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-641 study | Julie Nicole Graff; Joseph Burgents; Li Wen Liang; Arnulf Stenzl; | Clinical Trial In Progress | Clinical trial |
| P387 | A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer (PORTER) | Leo Nissola, MD; Karen Autio, MS, MD; Nina Bhardwaj, MD, PhD; Matthew D. Galsky, MD; Kristopher Wentzel, MD; Vanessa M. Lucey; Cheryl Selinsky, PhD; Christopher Perry; Christopher Cabanski, PhD; Ari J. Bitton; Justin Fairchild; Christine E. Horak, PhD; Jeffrey M. Skolnik, MD; Michael Yellin, MD; Ute Dugan, MD, PhD; Ramy Ibrahim, MD; Lawrence Fong, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune tolerance; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P388 | Pembrolizumab plus docetaxel and prednisone for enzalutamide- or abiraterone acetate–pretreated patients with metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-921 study | Neal Shore, MD; Daniel P. Petrylak, MD; Mostefa Bennamoun; Raffaele Ratta; Josep Piulats; Ben Li; Charles Schloss; Karim Fizazi; | Clinical Trial In Progress | Clinical trial |
| P389 | A Phase I Trial of Interleukin-2 (IL-2) and Pembrolizumab (Pembro) Combination Therapy for Patients with Advanced Renal Cell Carcinoma | Scott S. Tykodi, MD, PhD; Johanna Whitney; Sumia Dakhil; Eleanor L. Bergren; Vivian T. Nguyen; Samantha M. Kiriluk; Shailender Bhatia, MD; John A. Thompson, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P390 | Pembrolizumab plus olaparib vs enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer who experienced progression on chemotherapy: phase 3 KEYLYNK-010 study | Evan Y. Yu; Se Hoon Park; Yi-Hsiu Huang; Mostefa Bennamoun; Lu Xu; Jeri Kim; Emmanuel S. Antonarakis, MD; | Clinical Trial In Progress | Clinical trial |
| P391 | Randomized phase II trial of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed stage III or IV ovarian cancer | Lisa A. Abaid, MD; Richard L. Friedman, MD, PhD; John V. Brown, MD; Alberto A. Mendivil, MD; Tiffany L. Beck, MD; Bradley R. Corr; Leslie M. Randall; James R. Mason; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD, FACP; | Clinical Trial In Progress | Clinical trial; Dendritic cell; Neoantigens; Stem cell/cancer-initiating cell; Tumor antigens; Vaccine |
| P392 | Phase 1 combination study of the CHK1 inhibitor prexasertib (LY2606368) and anti-PD-L1 antibody LY3300054, in patients with high-grade serous ovarian cancer and other advanced solid tumors | Khanh T. Do; Claire Manuszak; Sarah E. Kelland; Allison P. Powers; Adrienne Anderson; Alona Muzikansky; Andrew Wolanski; Mariano Severgnini, MSc; Geoffrey Shapiro, MD, PhD; Khanh T. Do, MD; | Clinical Trial In Progress | Biomarkers; Clinical trial; Solid tumors; Targeted therapy; Tumor antigens |
| P393 | Single agent activity of a novel PD-1 inhibitor AGEN2034 in recurrent ovarian cancer. Subset analysis of phase I dose escalation NCT03104699 study | David M. O'Malley; John Hays; Charles Drescher; Jasgit Sachdev; Wilberto Nieves-Neira; Breelyn Wilky; Marylin Huang; Kathleen N. Moore; Waldo Ortuzar; Anna Wijatyk; Hagop Youssoufian; Remigiusz Kaleta, MD; Inbal Sapir; Christopher Dupont, PhD; Irina Shapiro; Debra Richardson, MD; | Clinical Trial In Progress | Biomarkers; Clinical study; Immune contexture; Solid tumors; Targeted therapy |
| P394 | A Phase 1 study of INCMGA00012, a PD-1 inhibitor, in patients with advanced solid tumors: Preliminary results for patients with advanced cervical cancer (POD1UM-101) | Janice J. Mehnert, MD; Luis Paz Ares, MD, PhD; Joanna Pikiel, Dr n. med.; Udai Banerji, PhD; Anna Kryzhanivska, MD; Nehal Lakhani, MD, PhD; Sebastian Ochsenreiter, Dr. med.; Tobias Arkenau, MD, PhD; Nawel Bourayou, MD; Deanna Kornacki, PhD; Chuan Tian, PhD; Thomas Condamine, PhD; Itziar Gardeazabal González; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Solid tumors |
| P395 | Phase 2/3 open-label trial of enoblituzumab in combination with MGA012, with and without chemotherapy, in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma | Fernanda I. Arnaldez; Charu Aggarwal, MD MPH; Scott Currence; Jan Baughman, MPH; Paul Moore, PhD; George R. Blumenschein, Jr., MD; Jon M. Wigginton, MD; Robert L. Ferris, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P396 | A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults with Head and Neck Cancer | Ezra Cohen, MD; Robert L. Ferris, MD, PhD; Douglas Adkins, MD; Dan P. Zandberg, MD; Arkadiusz Dudek, MD, PhD; Matthen Mathew; Lara Dunn, MD; Juneko E. Grilley-Olson, MD; Ammar Sukari, MD; Rebecca Redman, MD; Julie E. Bauman, MD, MPH; John M. Kaczmar, MD; Lisle Nabell, MD; Nabil F. Saba, MD; Eric Nadler, MD; Young J. Kim, MD; Ranee Mehra, MD; Nitya Nair, PhD; Somayeh Honarmand, MS; Richard E. Cutler Jr.; Barbara A. Burtness, MD; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical trial; Immune adjuvant; T cell |
| P397 | Interim analysis of the combination of durvalumab and cetuximab in a phase II trial of patients with recurrent and metastatic head and neck squamous cell carcinoma. | Shuchi Gulati, MD; Sarah Palackdharry; Layne Weatherford; Sarah Wilson; Shireen Desai; Aubrey Steele; Kashif M. Riaz; Vinita Takiar; Trisha W. Draper; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; NK/NK T cell; Solid tumors; Targeted therapy |
| P398 | miRNA-A and programmed death ligand 1 (PD-L1) expression in oral squamous cell carcinoma | Hong J. Hyung, MD. PhD; Yoon Ho Ji. Ko; Lee Hee JIn; Sang Hoon Jeon; | Clinical Trial In Progress | Immune suppression; Tumor microenvironment |
| P399 | Instructive conclusions from performing immune correlatives on IO trials: a meta-analysis of patient tumor and blood samples. | Patrick Lizotte, PhD; Megan Cavanaugh; Melissa Jean; Cloud Paweletz, PhD; | Clinical Trial In Progress | Checkpoint blockade; Immune monitoring |
| P400 | Sitravatinib and Nivolumab for resectable Oral cavity squamous cell carcinoma Window of opportunity study (SNOW) | Marc Oliva Bernal, MD; Douglas Chepeha, MD; Amy AP. Prawira, MD; Anna Spreafico, MD PhD; Scott Bratman, MD; Tina Shek, MD; John De Almeida, MD; Ivan Yeung, MD; Aaron Hansen; Andrew Hope, MD; David Goldstein, MD; Ralph Gilbert, MD; Doug Vines, BSc, MRT(N), CNMT; Patrick Gullane; Dale H. Brown, MD; Ilan Weinreb, MD; Bayardo Perez-Ordoñez, MD; Trevor Pugh, PhD; Pamela S. Ohashi, PhD; Ben Wang, PhD; Jonathan Irish, MD; Hirak Der-Torossianh, MD; Isan Chen, MD; Lillian Siu, MD; | Clinical Trial In Progress | Angiogenesis; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P401 | Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC): the phase 3 KEYNOTE-689 study | Ravindra Uppaluri, MD, PhD; Nancy Y. Lee, MD; William Westra; Ezra Cohen, MD; Robert I. Haddad; Stephane Temam; Christophe Le Tourneau; Rebecca Chernock; Sufia Safina; Arkadiy Klochikhin; Amichay Meirovitz; Irene Brana, MD; Joy Yang Ge; Ramona F. Swaby, MD; Cecilia Pinheiro; Douglas Adkins, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant; Radiotherapy |
| P402 | BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma | Michael R. Bishop, MD; Ian Flinn, MD; Peter Borchmann; Ulrich Jaeger; Jason R. Westin, MD; Nada Hamad; Duncan Purtill; Richard Greil; Simone Thomas; Takanori Teshima; Hideo Harigae; Carlos G. Garcia; Pere Barba; Abhinav Deol, MD; Paul Shaughnessy; Jessie Gu; Giovanna Andreola; Marcela Martinez Prieto; Lida Pacaud; Stephen J. Schuster, MD; | Clinical Trial In Progress | CAR T cells; Clinical trial; Leukemia/Lymphoma |
| P403 | Serum soluble CD25 may predict the early therapeutic response in pediatric patients with B-cell non-Hodgkin's lymphoma（B-NHL）during autologous chimeric antigen receptor T cell(CAR-T) therapy | Jing X. Guo; Yonghong Zhang, Professor; Juan Du, MD; Juan Du, MD; | Clinical Trial In Progress | B cell; CAR T cells; Clinical study; Cytokine; Leukemia/Lymphoma; Pediatric tumors |
| P404 | Developing canine CART-19 to fully leverage comparative oncology and inform human clinical trials | Kumudhini P. Haran, M.S; Ailian Xiong; Enrico Radaelli; Patrick J. Savickas; Avery Posey; Donald Siegel; Nicola Mason, B.Vet Med PhD; | Clinical Trial In Progress | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma |
| P405 | CASSIOPEIA: A phase 2 study evaluating efficacy and safety of tisagenlecleucel in first-line therapy for high-risk pediatric and young adult patients with B-ALL who are MRD positive at the EOC | Shannon L. Maude, MD, PhD; Hunger Stephen, MD; Jochen Buechner, MD; Stephen A. Grupp, MD; Susana Rives; Andre Baruchel; John Levine; Joerg Krueger; Theodore W. Laetsch; Marianne RS. Ifversen; Aiesha Zia; Jaclyn Davis; Eric Bleickardt; Mignon Loh; | Clinical Trial In Progress | B cell; CAR T cells; Clinical trial; Leukemia/Lymphoma; T cell |
| P406 | Interleukin-1 blockade to prevent severe immune effector cell-associated neurotoxicity syndrome; Trial in progress | Caspian Oliai, MD; Anna Crosetti; John M. Timmerman, MD | Clinical Trial In Progress | CAR T cells; Cytokine; Inflammation; Leukemia/Lymphoma |
| P407 | Phase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation | Masatoshi Kudo, MD, PhD; Andrew Zhu; Arndt Vogel; Thomas Yau; Jian Zhou; Erluo Chen; Usha Malhotra; Abby Siegel; Ann-Lii Cheng, MD PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant; Solid tumors |
| P408 | LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma | Josep M. Llovet; Masatoshi Kudo, MD, PhD; Ann-Lii Cheng, MD PhD; Richard Finn; Peter Galle; Shuichi Kaneko, MD PhD; Tim Meyer; Shukui Qin; Corina E. Dutcus; Erluo Chen; Leonid Dubrovsky; Abby Siegel; Andrew Zhu; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Targeted therapy |
| P409 | A case report of personalized neoantigen peptide vaccine in treating patients with biliary tract cancer | Fang Yong; Fan Mo; Jiawei Shou; Huimin Wang; Lin Chen; Shanshan Zhang; Hongsen Li; Weidong Han; Hongming Pan; Shuqing Chen; | Clinical Trial In Progress | Bioinformatics; Clinical trial; Neoantigens; Solid tumors; Vaccine |
| P410 | Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with durvalumab in patients with advanced non-small cell lung cancer (NSCLC) | Ji-Youn Han, MD, PhD; Kyoung-Ho Pyo; Jea Hwan Kim; Chun-Feng Xin; Jin Kyung Lee; Sunjin Hwang; Seong-Jin Kim; Byoung Chul Cho, MD.phD; Byoung Chul Cho, MD.phD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical study; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P411 | Treating advanced non-small lung cancer (NSCLC) patients after checkpoint inhibitor treatment failure with a novel combination of Viagenpumatucel-L (HS-110) plus nivolumab | Daniel Morgensztern, MD; Saiama Waqar, MD; Lyudmila Bazhenova, MD; Rachel E. Sanborn, MD; Lori Mcdermott, RN, MSc; Jeff Hutchins, PhD; Luis E. Raez, MD, FACP, FCCP; Corey J. Langer, MD; Roger Cohen, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma; Vaccine |
| P412 | Validation of a Single-Blinded (Patients Only) Study Design for the Prevention of Premature Patient Consent Withdrawal in the Immuno-Oncology Trial DUBLIN-3 | Ramon Mohanlal, MD, PhD, MBA; Huang Lan, PhD; Ramon Mohanlal, MD, PhD, MBA; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Dendritic cell |
| P413 | A Phase 1b/2 study of galunisertib in combination with nivolumab in solid tumors and NSCLC | Ernest Nadal, MD, PhD; Mansoor N. Saleh, MD; Santiago Ponce Aix, MD; Maria Ochoa de Olza; Sandip P. Patel, MD; Scott J. Antonia, MD, PhD; Yumin Zhao, PhD; Ivelina Gueorguieva, PhD; Michael Man, PhD; Shawn T. Estrem, PhD; Emin Avsar; Wen Hong Lin; Karim Benhadji; Susan Guba; Inmaculada Ales Diaz; Ernest Nadal, MD, PhD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune suppression; Solid tumors |
| P414 | Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced non-small cell lung cancer patients | Michael Shafique, MD; Terrence L. Fisher, Jr., PhD; Elizabeth E. Evans, PhD; John E. Leonard, MD PhD; Desa Rae Pastore; Crystal Mallow, BS; Ernest S. Smith, PhD; Andreas Schroeder, MD, PhD; Kevin Chin; Joseph Beck; Megan A. Baumgart, MD; Ramaswany Govindan, MD; Nashat Y. Gabrail, MD; Jonathan W. Goldman, MD; Rachel E. Sanborn, MD; Alexander I. Spira, MD, PhD, FACP; Nagashree Seetharamu; Yanyan Lou, MD; Aaron Mansfield, MD; Maurice Zauderer, PhD; PhD; Terrence L. Fisher, Jr., PhD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Immune monitoring; Myeloid cells; MDSC; Regulatory T cell (Treg cell); Tumor microenvironment |
| P415 | Tumor Treating Fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in Phase 3 LUNAR Study | Uri Weinberg, MD PhD; Ori Farber; Moshe Giladi; Ze'ev Bomzon; Eilon D. Kirson; Uri Weinberg, MD PhD; Uri Weinberg, MD PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Coinhibition; Solid tumors |
| P416 | A phase 1 dose escalation with expansion study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AMV564 in subjects with advanced solid tumors | Raghad M. Abdul Kairm, MD; Anthony Tolcher, MD; Victoria Smith; Sterling C. Eckard, PhD; Jeanmarie Guenot; Patrick Chun; | Clinical Trial In Progress | Clinical trial; Immune suppression; Myeloid cells; MDSC; Solid tumors; T cell; Targeted therapy |
| P417 | ATLAS™ identifies relevant neoantigens for therapeutic anti-tumor vaccination and may serve as a biomarker for efficacy of immunotherapy of solid tumors | Parul Agnihotri; Tulin Dadali; Parul Agnihotri, PhD; | Clinical Trial In Progress | Antigen presenting cells; Biomarkers; Clinical study; Clinical trial; Dendritic cell; Neoantigens; Solid tumors; T cell; Targeted therapy; Vaccine |
| P418 | Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis | Pablo Fernandez-Penas, MD, PhD; Matteo S. Carlino, MBBS, PhD, BMedSC, F; Victoria Atkinson, MD; Melinda Telli; Rohit Joshi; Sajev Thomas; Katy Tsai, MD; Rachel Roberts-Thomson; Andrew Haydon, MBBS PhD; Andrew Mant; Tom Van Hagen; Katharine Cuff; Bianca Devitt; Igor Puzanov, MD, MSCI, FACP; Marcus O. Butler, MD; Catalin Mihalcioiu; Hatem Soliman, MD; John Hyngstrom, MD; Mecker Moller; Gregory A. Daniels, MD, PhD; Eric D. Whitman, MD, FACS; Erica Browning, BS; Reneta Hermiz; Lauren Svenson; Jack Y. Lee; Donna Bannavong; Jendy Sell; Kellie Malloy; David A. Canton, PhD; Christopher G. Twitty; Adil Daud, MBBS MD; Alain Algazi, MD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Cytokine; Immune monitoring; MDSC; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P419 | A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC) | Johanna Bendell, MD; Drew Rasco, MD; Wungki Park, MD; Lei Zhou, MD, MS; Anna Galkin, PhD; Debbie Slee, PhD; Laura L. Carter, PhD; David Nickle, PhD; Rebecca Tran, MS; Jack Li, PhD; Beatrice Ferguson, MS; Jakob Dupont, MD; Vineet Gupta, PhD; Eileen O'Reilly; | Clinical Trial In Progress | Antibody; Immune suppression; MDSC; Solid tumors |
| P420 | Broad immunogenicity from GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumor neoantigens | Roger Cohen, MD; Melissa L. Johnson, MD; Przemyslaw Twardowski, MD; Mark Stein, MD; Ulka N. Vaishampayan, MD; Maura L. Gillison, MD, PhD; Lisa K. McNeil, PhD; Louisa Dowal, PhD; James Foti, PhD; Parul Agnihotri, PhD; Daniel DeOliveira, PhD; Manish Jain, MS; Jessica Price; Richard Hernandez; Arthur P. DeCillis, MD; Narinderjeet Singh, MS, MBA; Thomas A. Davis, MD; Jessica B. Flechtner, PhD; | Clinical Trial In Progress | Clinical trial; Immune adjuvant; Immune monitoring; Immune suppression; Neoantigens; Solid tumors; T cell; T cell lineages; Tumor antigens; Vaccine |
| P421 | Phase 1 study of the safety, tolerability and preliminary anti-tumor activity of COM701 monotherapy in patients with advanced solid tumors. | Ecaterina I. Dumbrava, MD; Gini F. Fleming, MD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Amita Patnaik, MD FRCP(C); Kyriakos P. Papadopoulos, MD; Adam ElNaggar, MD; John Hunter, PhD; Judy Olweny; Adeboye H. Adewoye, MD; Bartosz Chmielowski, MD, PhD; Dale Shepard, MD PhD; Manish R. Sharma, MD; Emerson Lim, MD; Daniel Vaena, MD; Drew Rasco, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P422 | Phase 1 study of COM701 monotherapy and in combination with nivolumab in patients with advanced solid tumors. | Ecaterina Dumbrava, MD; Gini Fleming, MD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Amita Patnaik, MD FRCP(C); Kyriakos P. Papadopoulos, MD; Adam ElNaggar, MD; John Hunter, PhD; Judy Olweny; Adewoye H. Adewoye, MD; Adeboye H. Adewoye, MD; Bartosz Chmielowski, MD, PhD; Dale Shepard, MD PhD; Manish R. Sharma, MD; Emerson Lim, MD; Daniel Vaena, MD; Drew Rasco, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P423 | SURPASS trial design: A phase 1 dose escalation trial to assess safety and efficacy of ADP-A2M4CD8 in HLA-A2+ patients with MAGE-A4+ tumors | Paula M. Fracasso, MD, PhD; David S. Hong, MD; Marcus Butler; Melissa L. Johnson, MD; Tanner Johanns; Francine Brophy; Rebecca Dryer-Minnerly, PhD; Trupti Trivedi, MS; Rafael Amado, MD; Paula M. Fracasso, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor antigens |
| P424 | Preliminary safety, efficacy and immunogenicity results from a phase 1/2a study (DIRECT-01) of cancer neoantigen DNA vaccine VB10.NEO in patients with locally advanced or metastatic solid tumors | Jürgen Krauss; Angela Krackhardt; Elke Jaeger; Anja Williams; Reza Rafiyan; LIsa Gerner; Monika Sekelja; Agnete B. Fredriksen, PhD; Karoline W. Schjetne; Mads Axelsen; Agnete B. Fredriksen, PhD; Hedda Wold, MSc; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Vaccine |
| P425 | Phase 1b study of GX-I7, a long-acting interleukin-7, evaluating the safety, pharmacokinetics and pharmacodynamics profiles in patients with advanced solid cancers | Minkyu Heo; Tae Won Kim, MD, PhD; | Clinical Trial In Progress | Biomarkers; Chemokine; Clinical study; Clinical trial; Cytokine; Immune adjuvant; Immune monitoring; Solid tumors; T cell |
| P426 | A first-in-human phase 1, multicenter trial of toll-like receptor (TLR) 7 agonist DSP-0509 as monotherapy and in combination with pembrolizumab in adult patients with advanced solid tumors | Shadia Jalal, MD; Jared Weiss, MD; Anthony J. Olszanski, MD, RPh; Jordan Berlin, MD; Makoto Origuchi; Zhonggai Li; Bella Ertik; Hongliang Cai; Daniel Clancy; Jose Iglesias; Vivek Subbiah, MD; Shadia Jalal, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR |
| P427 | A Phase 1 Study of IMC-001, Novel Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors | Bhumsuk Keam, MD, PhD; Tae Min Kim, MD, PhD; Do-Youn Oh, MD, PhD; Chan-Young Ock, MD, PhD; Won Ki Kang, MD, PhD; Yeon Hee Park, MD, PhD; Jeeyun Lee, MD, PhD; Ji Hye Lee, MD; Yun Jeong Song, MD; Young Suk Park, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Antibody; Clinical study; Clinical trial; Solid tumors; T cell |
| P428 | A phase 1 study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as stand-alone and in combination with BI 754091, a PD-1 inhibitor, in patients with advanced solid tumours | Nuria Kotecki, MD; Philippe Cassier; Jean-Pierre Delord, MD; Stéphane Champiat; Christiane Jungels; Armelle Vinceneux; Iphigenie Korakis; Richard Huhn; Nicolas Poirier; Dominique Costantini; Bérangère Vasseur; Aurélien Marabelle; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Targeted therapy |
| P429 | A phase 1/2a dose escalation and expansion study of HPN536, a mesothelin-targeting T cell engager, in patients with advanced cancers expressing mesothelin who have failed standard therapy | Erika P. Hamilton, MD; Richard Austin, PhD; Sue Hirabayashi; Che-Leung Law, PhD; Bryan Lemon, PhD; Holger Wesche, PhD; Debra Richardson, MD; | Clinical Trial In Progress | Antibody; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P430 | Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination with a PD-1 Inhibitor in Adult Subjects with Advanced or Metastatic Solid Tumors | David Luo; Raghad Abdul-Karim, MD; Arun Azad, MD; Joanna Bendell, MD; Hui Gan, MBBS PhD; Filip Janku, MD, PhD; Shiraj Sen, MD, PhD; Tira Tan, MBBS; Judy S. Wang, MD; Lisa Schechet; Lauren Baker, PhD; Joseph A. Leveque, MD; Tarek Meniawy, MBBS FRACP; | Clinical Trial In Progress | Clinical study; Clinical trial; Cytokine; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P431 | Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (TG-1501) in oncology patients | Lin Lin, PhD; James Hilbert; Leonid Gorelik; Jian-Ping Tang; James Oliviero; Joshua Apgar; Lore Gruenbaum, PhD; John Burke; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs) |
| P432 | A phase 1 dose-escalation study of safety, tolerability, and pharmacokinetics (PK) of ABBV-368 monotherapy and combination in patients (pts) with locally advanced or metastatic solid tumors | Christophe Le Tourneau; Wu-Chou Su, MD; Ki Y. Chung, MD; Patricia LoRusso, DO; Chia-Chi Lin, MD, PhD; Fabrice Barlesi, MD, PhD; Her-Shyong Shiah; Eric Angevin, MD; Alexander I. Spira, MD, PhD, FACP; Amita Patnaik, MD FRCP(C); John D. Powderly, II, MD, CPI; Dimitrios Colevas; Helen Chew, MD; Maulik Patel, PharmD, PhD; Stacie L. Lambert; Yan Li; Daniel Da Costa; Martha E. Blaney, PharmD; Michael A. McDevitt, MD, PhD; Philippe Cassier; | Clinical Trial In Progress | Antibody; Clinical trial; Regulatory T cell (Treg cell); Solid tumors |
| P433 | Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors | M R. Middleton, MD PhD; Joseph Sacco; Jaime Merchan; Amber Thomassen; Brendan D. Curti, MD; Ari M. VanderWalde, MD, MPH, MBioeth; Anna C. Olsson-Brown, MBChB (Hons), BSc (Hons); Francesca Aroldi; Nicos Fotiadis; Scott Baum; Howard L. Kaufman, MD, FACS; Kevin Harrington, MD; | Clinical Trial In Progress | Clinical study; Tumor microenvironment |
| P434 | A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers | Mehrdad Mobasher; Richard A. Miller; Brian Munneke; Deborah Strahs; Gabriel Luciano; Emily C. Piccione, PhD; Suresh Mahabhashyam; Jaime Merchan; John D. Powderly, II, MD, CPI; Lauren Harshman, MD; Minal Barve; Walter Stadler, MD; Patricia LoRusso, DO; Melissa Johnson; Abhishek Tripathi, MD; Sumanta K. Pal, MD; Ben Markman, MBBS FRACP; Jason J. Luke, MD, FACP; Thomas U. Marron, MD PhD; | Clinical Trial In Progress | Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; Solid tumors; Targeted therapy |
| P435 | A Window of Opportunity Trial Using Intratumoral Injection of Glatiramer as an Immune Modulator in Patients with Resectable Head and Neck and Cutaneous Squamous Cell Cancer | Ghulam Rehman Mohyuddin, MD; Joaquina C. Baranda, MD; Andres Bur; Lisa Shnayder; Kiran Kakarala; Terry Tsue; Prakash Neupane; Gregory Gan; Joshua Mammen; Daniel Aires; Sufi Thomas; Stephen Williamson; Nelli Lakis; Rashna Madan; Prabhakar Chalise; Scott Weir; Andrew Godwin; Greg Reed; Cory Berkland; | Clinical Trial In Progress | Biomarkers; Clinical trial; NK/NK T cell; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| P436 | Phase 2 study of lenvatinib plus pembrolizumab in previously treated patients with solid tumors: LEAP-005 | Ravit Geva, MD; Seock-Ah Im; Zarnie Lwin; Susan Weil; Lei Xu; Anne Morosky; Kevin G. Norwood, MD; Hyun Cheol Chung, MD, PhD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P437 | Disease-related biomarkers are associated with extended progression free survival after treatment with NEO-PV-01 in combination with anti-PD1 in patients with metastatic cancers | Patrick A. Ott, MD, PhD; Ramaswamy Govindan, MD; Aung Naing, MD, FACP; Terence Friedlander, MD; Kim A. Margolin, MD; Jessica J. Lin, MD; Nina Bhardwaj, MD, PhD; Matthew Hellmann, MD; Mark Awad, MD PhD; Amy Wanamaker; Lisa D. Cleary; Michael Rooney; Julian Scherer, PhD; Meghan E. Bushway; Melissa Moles; Zakaria Khondker; Richard B. Gaynor, MD; Lakshmi Srinivasan, Ph.D; Andrew Chi; Joel Greshock; Siwen Hu-Lieskovan, MD, PhD; | Clinical Trial In Progress | Bioinformatics; Biomarkers; Clinical study; Clinical trial; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| P438 | Phase 2 Multicenter Trial of ICOS agonist vopratelimab and a CTLA-4 inhibitor in PD-1/PD-L1 inhibitor experienced adult subjects with Non-small Cell Lung Cancer or Urothelial Cancer (EMERGE) | Russell Pachynski, MD; Ramaswamy Govindan, MD; Ellen Hooper, MD; Christopher Harvey, PhD; Amanda Hanson; Sean M. Lacey, MA Biostatistics; Rachel McComb; Courtney Hart; Haley Laken; Johan Baeck; Elizabeth G. Trehu, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Cytokine; Immune suppression; T cell; Targeted therapy; Tumor antigens |
| P439 | Phase 1 First in Human Study of Programmed Cell Death Receptor-1(PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects with Advanced Refractory Solid Tumor Malignancies | Kyriakos P. Papadopoulos, MD; Gerald S. Falchook, MD; Nehal Lakhani, MD, PhD; Gosia Riley; Jian Xu, PhD; Johan Baeck; Gilad S. Gordon; Elizabeth G. Trehu, MD; Judy S. Wang, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors; T cell |
| P440 | Phase 1/1b Multicenter Trial of TPST-1120, a Peroxisome Proliferator-Activated Receptor Alpha (PPARα) Antagonist as a Single Agent (SA) or in Combination in Subjects with Advanced Cancers | John D. Powderly, II, MD, CPI; Saurin Chokshi, MD; Johanna Bendell, MD; Leisha A. Emens, MD, PhD; Jason J. Luke, MD, FACP; Brian Francica; Chan C. Whiting, PhD; Thomas W. Dubensky, Jr., PhD; Ginna G. Laport, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Metabolism; Solid tumors; Tumor microenvironment |
| P441 | ARTISTRY-2: a phase 1/2 study of subcutaneously administrated ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | John D. Powderly, II, MD, CPI; Bradley C. Carthon, MD, PhD; Marc S. Ernstoff, MD; Anthony J. Olszanski, MD, RPh; Stephen V. Liu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Lei Sun, PhD; Emily L. Putiri, PhD; Yan Wang, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Ulka N. Vaishampayan, MD; | Clinical Trial In Progress | Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors |
| P442 | A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors | Amy AP. Prawira, MD; Jermaine Coward; Hui Gan, MBBS PhD; James Kuo; Michael Millward; Gary Richardson; Wei Deng; Siddhartha Mitra; Maike Schmidt; Hong Xiang, PhD; Lisa Horvath; Amy AP. Prawira, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell |
| P443 | Expansion cohorts of non-small cell lung cancer (NSCLC) and castration resistant prostate cancer (CRPC) in COSMIC-021, a phase 1b study of cabozantinib plus atezolizumab | Nick Salgia, PhD; Sumanta K. Pal, MD; Santiago Ponce Aix, MD; Yohan Loriot; Robert Dreicer; Ulka N. Vaishampayan, MD; Toni K. Choueiri; Patrick Schöffski; Giri Ramsingh; Amy Liu; Farah L. Lim; Joel Neal, MD, PhD; Neeraj Agarwal, MD; | Clinical Trial In Progress | Clinical trial; Solid tumors |
| P444 | The Quest for Highly Potent Human Papillomavirus-Specific T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies | Pei Yun Teo, PhD; Sandhya Sharma, BSc.; Alex Salyer; Dimitrios L. Wagner; Benjamin Shin; Sachin Thakar; Li-Chun Huang; Shian Jiun Shih; Carlos Ramos; Cliona M. Rooney, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P445 | Preliminary results of a Phase 1 trial with a personalized neoantigen vaccine (ADXS-NEO) in advanced and refractory cancer patients | Frank Y. Tsai, MD; Jonathan W. Goldman, MD; Marc R. Matrana; Sumitra Sheeri; John Heyburn; Megan Parsi; Andres A. Gutierrez, MD PhD; Joel R. Hecht; Joel R. Hecht; | Clinical Trial In Progress | Antigen presenting cells; Biomarkers; Clinical study; Neoantigens; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P446 | A Novel Regulatory T Cell-Targeted Immunotherapy by targeting their Crucial Signal by HSP90 Inhibitors | Ayaka Tsuge, MD; Yosuke Togashi, MD, PhD; Kohei Shitara, MD; Hiroyoshi Nishikawa, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical trial; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment |
| P447 | ALKS 4230, an engineered IL-2 fusion protein, in monotherapy dose-escalation and combination therapy with pembrolizumab in patients with solid tumors: ARTISTRY-1 trial | Ulka N. Vaishampayan, MD; Jameel Muzaffar, MD; Vamsidhar Velcheti, MD, FACP; Christopher J. Hoimes, DO; Lucy Gilbert, MD; David F. McDermott, MD; Anna Spreafico, MD PhD; Quincy Chu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Harald Mackenzie, MB; Lei Sun, PhD; Emily L. Putiri, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Marc S. Ernstoff, MD; | Clinical Trial In Progress | Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors |
| P448 | Phase I Study of Veliparib and Nivolumab in Adults with Refractory Advanced Solid Tumor and Lymphoma | Young Kwang Chae, MD; Pedro Viveiros, MD; Sheetal Kircher; Valerie Nelson; Aparna Kalyan; Devalingam Mahalingam; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant |
| P449 | Pharmacodynamic biomarker characterization of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy | Hong Wan, PhD; Laura Q. Chow, MD; Justin F. Gainor, MD; Nehal Lakhani, MD, PhD; Hyun C. Chung, MD, PhD; Keun-Wook Lee, MD; Jeeyun Lee, MD, PhD; Patricia LoRusso, DO; Yung-Jue Bang, MD PhD; Stephen Hodi; Wells Messersmith, MD; Philip Fanning, PhD; Pierre Squifflet; Feng Jin; Tracy Kuo; Sangeetha Bollini; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Immune suppression; Monocyte/Macrophage; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P450 | A Phase I/IIa, Open-label, Dose-Escalation and expansion study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients with Advanced Solid Tumors | Jin Li; Ye Guo; Wei Peng; Junli Xue; Wei Zhao; Xiaoxiao Ge; Liqiong Xue; Wenbo Tang; Li Zhou; Min Zhang; Bingshi Guo; Liping Wang, MD; Jiyuan Guo; Feifei Cui, PhD; Haiyun Suo; | Clinical Trial In Progress | Clinical trial; Cytokine; Solid tumors; T cell |
| P451 | First-in-human study of CD40 agonist MEDI5083 in advanced solid tumors with durvalumab administered sequentially or concurrently | Ben Tran, MBBS FRACP; Mark Voskoboynik; Johanna Bendell, MD; Martin Gutierrez, MD; Charlotte R. Lemech, MBBS BSc(med) MD(res); Daphne Day; Sophia Frentzas; Ignacio Garrido-Laguna; Chris DelNagro; Fujun Wang; Charles Ferte, MD, PhD; Mayukh Das; Benedito A. Carneiro, MD; Ben Tran, MBBS FRACP; | Clinical Trial In Progress | Antibody; Antigen presenting cells; Checkpoint blockade; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P452 | SPEARHEAD-1 trial design: A phase 2, single arm, open-label clinical trial of ADP-A2M4 SPEAR T-cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma | Dejka Araujo, MD; Jean-Yves Blay; Sandra Strauss; Claudia Valverde; Erin Van Winkle; Malini Iyengar, PhD; Rafael Amado, MD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P453 | Autologous T cells with NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-A*02+ previously-treated and -untreated advanced metastatic/unresectable synovial sarcoma: A master protocol study design | Sandra P. D'Angelo, MD; Jean-Yves Blay; Warren Chow; George D. Demetri; Fiona Thistlethwaite, MD, PhD; Michael Wagner; David Loeb; Steven Attia; Albiruni R. Razak; John Haanen, MD PhD; Aisha N. Hasan, MBBS MD; Julia Billiard; Laura Pearce; Yuehui Wu; Ran Ji; Laura Johnson; Chandra Srinath; Aiman Shalabi; Sandra Strauss; Katherine Thornton; Crystal L. Mackall, MD; William Tap; Brian Van Tine, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; CAR T cells; Clinical trial; T cell; Targeted therapy |
| P454 | Induction of serum CXCL10 by tebentafusp, a gp100-CD3 bispecific fusion protein, was associated with survival in uveal melanoma in a Phase I/II Study | Marcus O. Butler, MD; Brandon W. Higgs; Cheryl McAlpine, MSN; Joseph Sacco; Jessica C. Hassel, MD; Shaad E. Abedin, MD, FACP; Koustubh Ranade, PhD; Richard Carvajal, MD; | Clinical Trial In Progress | Biomarkers; Clinical study; Clinical trial; Solid tumors; Tumor antigens |
| P455 | A randomized phase 2 study of neoadjuvant talimogene laherparepvec (T-VEC) plus surgery vs surgery for resectable stage IIIB-IVM1a melanoma: 2-year primary analysis of recurrence-free survival (RFS) | Reinhard Dummer, MD; David E. Gyorki; John Hyngstrom, MD; Adam C. Berger, FACS, MD; Robert M. Conry, MD; Lev Demidov; Anjali Sharma; Sheryl A. Treichel; Kevin Gorski; Abraham Anderson, PhD; Mark Faries; Merrick Ross, MD; | Clinical Trial In Progress | Biomarkers; Clinical study; Clinical trial; Immune contexture; Inflammation; Solid tumors; Surgery |
| P456 | KEYNOTE-630: phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma | Jessica L. Geiger; Gregory A. Daniels, MD, PhD; Ezra Cohen, MD; Joy Yang Ge; Burak Gumuscu, MD PhD; Ramona F. Swaby, MD; Anne Lynn S. Chang; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune adjuvant; Solid tumors |
| P457 | Randomized Phase II Neoadjuvant Study: PD-1 Inhibitor TSR-042 vs. Combination PD-1 Inhibitor TSR-042 and Tim-3 Inhibitor TSR-022 in Borderline Resectable Stage III or Oligometastatic Stage IV Melanoma | Zahra Kelly, DO; Yana G. Najjar, MD; Hassane M. Zarour, MD; John M. Kirkwood, MD; Suthee Rapisuwon, MD; Hong Wang; Marc S. Ernstoff, MD; Joseph J. Drabick, MD, FACP, FIDSA; Diwakar Davar, MD; Mohan Bala; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell |
| P458 | A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells plus talimogene laherparepvec (T-VEC) in patients with advanced melanoma | Julia Katharina Schwarze, MD, MSc; Gil Awada; Louise Cras; Inès Dufait; Ramses Forsyth; Ivan Van Riet; Bart Neyns; | Clinical Trial In Progress | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; Solid tumors; Tumor microenvironment; Vaccine |
| P459 | New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor | Chengfei Pu; Lei Xiao, PhD; | Clinical Trial In Progress | CAR T cells; Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy; Tumor antigens |
| P460 | A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer | Hoyoung M. Maeng, MD; Lauren V. Wood, MD; Seth Steinberg; David F. Stroncek, MD; Masaki Terabe, PhD; Jay A. Berzofsky, MD, PhD; | Clinical Trial In Progress | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; Solid tumors; T cell; Tumor antigens; Vaccine |
| P461 | Phase 1b study of INCMGA00012, a programmed cell death-1 (PD-1) inhibitor, in combination with chemotherapy in patients with advanced solid tumors (POD1UM-105) | David Planchard, MD, PhD; Jill Bowman; Nawel Bourayou, MD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors |
| P858 | An Open-Label, Multi-center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with Cemiplimab in Subjects with Newly-Diagnosed Glioblastoma (GBM) | Jeffrey Skolnik, MD , David Reardon, MD, Steven Brem, MD, Arati Desai, Stephen Bagley, Sylvia Kurz, Macarena de la Fuente, Seema Nagpal, Mary Welch, Brian Sacchetta, Sarah Bartra, Amy-Lee Bredlau, Israel Lowy, MD, PhD, Kimberly Kraynyak, BS PhD, Matthew Morrow, Trevor McMullan, Jean Boyer, PhD | Clinical Trial In Progress | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Clinical trial; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P859 | Association of immunopharmacodynamic responses of Imprime PGG plus Pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy | Nadine Ottoson, BS, Nandita Bose, PhD , Anissa Chan, PhD, Xiaohong Qiu, BS, Ben Harrison, MS, Richard Walsh, BS, Paulette Mattson, BFA, Michele Gargano, MS, Joanna Cox, MD, Michael Chisamore, PhD, Mark Uhlik, PhD, Jeremy Graff, PhD | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Monocyte/Macrophage; Myeloid cells; Solid tumors |
| P860 | Results from a combination of OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a Phase 1 dose expansion cohort | Alberto Chiappori, MD , John Thompson, Fredericus Eskens, Jean-Philippe Spano, Toshihiko Doi, MD, PhD, Omid Hamid, MD, Adi Diab, MD, Naiyer Rizvi, MD, Siwen Hu-Lieskovan, MD, PhD, Willeke Ros, MSc0, Jacob Thomas, Alison Forgie, Wenjing Yang, Ken Liao, Ray Li, Farhad Kazazi, Jeffrey Chou, MD PhD, Anthony El khoueiry | Clinical Trial In Progress | Antibody; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P862 | Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with Imprime PGG and Pembrolizumab | Anissa Chan, PhD, Nandita Bose, PhD , Nandita Bose, PhD, Nadine Ottoson, BS, Xiaohong Qiu, BS, Ben Harrison, MS, Richard Walsh, BS, Paulette Mattson, BFA, Michele Gargano, MS, Joanna Cox, MD, Michael Chisamore, PhD, Mark Uhlik, PhD, Jeremy Graff, PhD | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Immune suppression; Myeloid cells; T cell |
| P863 | KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma | Michele Maio, MD, PhD , Matteo Carlino, MBBS, PhD, BMedSC, F, Anthony Joshua, Elaine McWhirter, Antoni Ribas, MD, PhD, Paolo Ascierto, Wilson Miller Jr., Marcus Butler, MD, Pier Ferrucci, Robert Zielinski, Michele Del Vecchio0, Eduard Gasal, Razi Ghori, PhD, Scott Diede, MD PhD, Elizabeth Croydon, Omid Hamid, MD | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P864 | Combination of fecal microbiota transplantation from healthy donors with anti-PD1 immunotherapy in treatment-naïve advanced or metastatic melanoma patients | Saman Maleki, PhD , John Lenehan, Jeremy Burton, Michael Silverman, Seema Nair Parvathy, Mikal El-Hajjar, Mithunah Krishnamoorthy | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Microbiome; T cell |
| P865 | Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies - independent review committee data update | Amod Sarnaik, MD, Nikhil Khushalani, MD, Jason Chesney, MD, Harriet Kluger, MD, Brendan Curti, MD, Karl Lewis, MD, Theresa Medina, MD, Sajeve Thomas, Anna Pavlick, MD, MBA, Eric Whitman, MD, FACS, Salvador Algarra, Pippa Corrie, PhD, BMBCh, FRCP0, Omid Hamid, MD, Jose Lutzky, MD, FACP, Judit Olah, MD, PhD, Jeffrey Weber, MD, PhD, James Larkin, MD, Wen Shi, Kelly DiTrapani, RN, BSN, Harry Qin, PhD, Mariam Mirgoli, Renee Wu, Toshimi Takamura, BS, Maria Fardis, PhD, MBA, John Kirkwood, MD | Clinical Trial In Progress | Adoptive immunotherapy; Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
© 2019 Society for Immunotherapy of Cancer (SITC). All rights reserved. SITC Meeting Code of Conduct.
